Epithelial toll-like receptor 9 signaling in colorectal inflammation and cancer: Clinico-pathogenic aspects

World Journal of Gastroenterology

Volumn 19, Issue 26, 2013, Pages 4119-4126

  Furi, István ^a   Sipos, Ferenc ^a   Germann, Tiana M ^a   Kalmár, Alexandra ^a   Tulassay, Zsolt ^b   Molnár, Béla ^b   Muzes, Györgyi ^a  

^a SEMMELWEIS UNIVERSITY   (Hungary)

^b INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

Author keywords

Colorectal cancer; DNA based immunomodulatory sequences; Inflammatory bowel diseases; Synthetic oligodeoxynucleotide sequences; Toll like receptor 9

Indexed keywords

CETUXIMAB; CPG OLIGODEOXYNUCLEOTIDE; DEXTRAN SULFATE; EPIDERMAL GROWTH FACTOR RECEPTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERFERON; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE 1; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE 4; INTERLEUKIN 12; INTERLEUKIN 6; K RAS PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; PANITUMUMAB; TOLL LIKE RECEPTOR 9; TOLL LIKE RECEPTOR AGONIST; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 6;

CARCINOGENESIS; COLITIS; COLONOSCOPY; COLORECTAL CANCER; CPG ISLAND; CYTOKINE PRODUCTION; DISEASE SEVERITY; GENE EXPRESSION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOSTIMULATION; INFLAMMATION; NONHUMAN; NUCLEOTIDE SEQUENCE; REVIEW; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; T LYMPHOCYTE;

EID: 84880102029     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v19.i26.4119     Document Type: Review

References (63)

1. Wiemann B, Starnes CO. Coley's toxins, tumor necrosis factor and cancer research: a historical perspective. Pharmacol Ther 1994; 64: 529-564 [PMID: 7724661 DOI: 10.1016/0163-72 58(94)90023-X]
2. Tokunaga T, Yamamoto H, Shimada S, Abe H, Fukuda T, Fujisawa Y, Furutani Y, Yano O, Kataoka T, Sudo T. Antitumor activity of deoxyribonucleic acid fraction from Mycobacterium bovis BCG. I. Isolation, physicochemical characterization, and antitumor activity. J Natl Cancer Inst 1984; 72: 955-962 [PMID: 6200641]
3. Yamamoto S, Yamamoto T, Shimada S, Kuramoto E, Yano O, Kataoka T, Tokunaga T. DNA from bacteria, but not from vertebrates, induces interferons, activates natural killer cells and inhibits tumor growth. Microbiol Immunol 1992; 36: 983-997 [PMID: 1281260]
4. Yamamoto T, Yamamoto S, Kataoka T, Komuro K, Kohase M, Tokunaga T. Synthetic oligonucleotides with certain palindromes stimulate interferon production of human peripheral blood lymphocytes in vitro. Jpn J Cancer Res 1994; 85: 775-779 [PMID: 7523351 DOI: 10.1111/j.1349-7006.1994. tb02947. x]
5. Hemmi H, Takeuchi O, Kawai T, Kaisho T, Sato S, Sanjo H, Matsumoto M, Hoshino K, Wagner H, Takeda K, Akira S. A Toll-like receptor recognizes bacterial DNA. Nature 2000; 408: 740-745 [PMID: 11130078 DOI: 10.1038/35047123]
6. Jurk M, Vollmer J. Therapeutic applications of synthetic CpG oligodeoxynucleotides as TLR9 agonists for immune modulation. BioDrugs 2007; 21: 387-401 [PMID: 18020622 DOI: 10.2165/00063030-200721060-00006]
7. Sipos F, Muzes G. Isolated lymphoid follicles in colon: switch points between inflammation and colorectal cancer? World J Gastroenterol 2011; 17: 1666-1673 [PMID: 21483625 DOI: 10.3748/wjg. v17. i13.1666]
8. Cashman SB, Morgan JG. Transcriptional analysis of Toll-like receptors expression in M cells. Mol Immunol 2009; 47: 365-372 [PMID: 19781788 DOI: 10.1016/ j. molimm.2009.09.007]
9. Török HP, Glas J, Endres I, Tonenchi L, Teshome MY, Wetzke M, Klein W, Lohse P, Ochsenkühn T, Folwaczny M, Göke B, Folwaczny C, Müller-Myhsok B, Brand S. Epistasis between Toll-like receptor-9 polymorphisms and variants in NOD2 and IL23R modulates susceptibility to Crohn's disease. Am J Gastroenterol 2009; 104: 1723-1733 [PMID: 19455129 DOI: 10.1038/ajg.2009.184]
10. Baumgart DC, Buning C, Geerdts L, Schmidt HH, Genschel J, Fiedler T, Gentz E, Molnar T, Nagy F, Lonovics J, Lochs H, Wiedenmann B, Nickel R, Witt H, Dignass A. The c.1-260C& gt; T promoter variant of CD14 but not the c.896A& gt; G (p. D299G) variant of toll-like receptor 4 (TLR4) genes is associated with inflammatory bowel disease. Digestion 2007; 76: 196-202 [PMID: 18174680 DOI: 10.1159/000112646]
11. De Jager PL, Franchimont D, Waliszewska A, Bitton A, Cohen A, Langelier D, Belaiche J, Vermeire S, Farwell L, Goris A, Libioulle C, Jani N, Dassopoulos T, Bromfield GP, Dubois B, Cho JH, Brant SR, Duerr RH, Yang H, Rotter JI, Silverberg MS, Steinhart AH, Daly MJ, Podolsky DK, Louis E, Hafler DA, Rioux JD. The role of the Toll receptor pathway in susceptibility to inflammatory bowel diseases. Genes Immun 2007; 8: 387-397 [PMID: 17538633 DOI: 10.1038/ sj. gene.6364398]
12. Davoodi H, Seow HF. Variant Toll-like receptor4 (Asp299Gly and Thr399Ile alleles) and Toll-like receptor2 (Arg753Gln and Arg677Trp alleles) in colorectal cancer. Iran J Allergy Asthma Immunol 2011; 10: 91-99 [PMID: 21625017]
13. Slattery ML, Herrick JS, Bondurant KL, Wolff RK. Toll-like receptor genes and their association with colon and rectal cancer development and prognosis. Int J Cancer 2012; 130: 2974-2980 [PMID: 21792899 DOI: 10.1002/ijc.26314]
14. O'Neill LA. The interleukin-1 receptor/Toll-like receptor superfamily: 10 years of progress. Immunol Rev 2008; 226: 10-18 [PMID: 19161412 DOI: 10.1111/j.1600-065X.2008.00701. x]
15. Fischer M, Ehlers M. Toll-like receptors in autoimmunity. Ann N Y Acad Sci 2008; 1143: 21-34 [PMID: 19076342 DOI: 10.1196/annals.1443.012]
16. Lee J, Mo JH, Katakura K, Alkalay I, Rucker AN, Liu YT, Lee HK, Shen C, Cojocaru G, Shenouda S, Kagnoff M, Eckmann L, Ben-Neriah Y, Raz E. Maintenance of colonic homeostasis by distinctive apical TLR9 signalling in intestinal epithelial cells. Nat Cell Biol 2006; 8: 1327-1336 [PMID: 17128265 DOI: 10.1038/ncb1500]
17. Latz E, Schoenemeyer A, Visintin A, Fitzgerald KA, Monks BG, Knetter CF, Lien E, Nilsen NJ, Espevik T, Golenbock DT. TLR9 signals after translocating from the ER to CpG DNA in the lysosome. Nat Immunol 2004; 5: 190-198 [PMID: 14716310 DOI: 10.1038/ni1028]
18. Leifer CA, Kennedy MN, Mazzoni A, Lee C, Kruhlak MJ, Segal DM. TLR9 is localized in the endoplasmic reticulum prior to stimulation. J Immunol 2004; 173: 1179-1183 [PMID: 15240708]
19. Latz E, Visintin A, Espevik T, Golenbock DT. Mechanisms of TLR9 activation. J Endotoxin Res 2004; 10: 406-412 [PMID: 15588423 DOI: 10.1179/096805104225006525]
20. Espevik T, Latz E, Lien E, Monks B, Golenbock DT. Cell distributions and functions of Toll-like receptor 4 studied by fluorescent gene constructs. Scand J Infect Dis 2003; 35: 660-664 [PMID: 14620151 DOI: 10.1080/00365540310016493]
21. Akira S, Hemmi H. Recognition of pathogen-associated molecular patterns by TLR family. Immunol Lett 2003; 85: 85-95 [PMID: 12527213 DOI: 10.1016/S0165-2478(02)00228-6]
22. Kanzler H, Barrat FJ, Hessel EM, Coffman RL. Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists. Nat Med 2007; 13: 552-559 [PMID: 17479101 DOI: 10.1038/nm1589]
23. Pinto A, Morello S, Sorrentino R. Lung cancer and Toll-like receptors. Cancer Immunol Immunother 2011; 60: 1211-1220 [PMID: 21789594 DOI: 10.1007/s00262-011-1057-8]
24. Lamphier MS, Sirois CM, Verma A, Golenbock DT, Latz E. TLR9 and the recognition of self and non-self nucleic acids. Ann N Y Acad Sci 2006; 1082: 31-43 [PMID: 17145922 DOI: 10.1196/annals.1348.005]
25. Häcker H, Mischak H, Miethke T, Liptay S, Schmid R, Sparwasser T, Heeg K, Lipford GB, Wagner H. CpG-DNAspecific activation of antigen-presenting cells requires stress kinase activity and is preceded by non-specific endocytosis and endosomal maturation. EMBO J 1998; 17: 6230-6240 [PMID: 9799232 DOI: 10.1093/emboj/17.21.6230]
26. Zhu J, Mohan C. Toll-like receptor signaling pathways--therapeutic opportunities. Mediators Inflamm 2010; 2010: 781235 [PMID: 20981241]
27. Krieg AM. Therapeutic potential of Toll-like receptor 9 activation. Nat Rev Drug Discov 2006; 5: 471-484 [PMID: 16763660 DOI: 10.1038/nrd2059]
28. Klinman DM. Immunotherapeutic uses of CpG oligodeoxynucleotides. Nat Rev Immunol 2004; 4: 249-258 [PMID: 15057783 DOI: 10.1038/nri1329]
29. Liu Y, Luo X, Yang C, Yu S, Xu H. Three CpG oligodeoxynucleotide classes differentially enhance antigen-specific humoral and cellular immune responses in mice. Vaccine 2011; 29: 5778-5784 [PMID: 21664398 DOI: 10.1016/ j. vaccine.2011.05.087]
30. Vollmer J, Weeratna R, Payette P, Jurk M, Schetter C, Laucht M, Wader T, Tluk S, Liu M, Davis HL, Krieg AM. Charac-terization of three CpG oligodeoxynucleotide classes with distinct immunostimulatory activities. Eur J Immunol 2004; 34: 251-262 [PMID: 14971051 DOI: 10.1002/eji.200324032]
31. Krug A, Rothenfusser S, Hornung V, Jahrsdörfer B, Blackwell S, Ballas ZK, Endres S, Krieg AM, Hartmann G. Identification of CpG oligonucleotide sequences with high induction of IFN-alpha/beta in plasmacytoid dendritic cells. Eur J Immunol 2001; 31: 2154-2163 [PMID: 11449369 DOI: 10.1002/1521-4 141(200107)31]
32. Petermann I, Huebner C, Browning BL, Gearry RB, Barclay ML, Kennedy M, Roberts R, Shelling AN, Philpott M, Han DY, Ferguson LR. Interactions among genes influencing bacterial recognition increase IBD risk in a population-based New Zealand cohort. Hum Immunol 2009; 70: 440-446 [PMID: 19275920 DOI: 10.1016/j. humimm.2009.03.002]
33. Lammers KM, Ouburg S, Morré SA, Crusius JB, Gionchett P, Rizzello F, Morselli C, Caramelli E, Conte R, Poggioli G, Campieri M, Peña AS. Combined carriership of TLR9-1237C and CD14-260T alleles enhances the risk of developing chronic relapsing pouchitis. World J Gastroenterol 2005; 11: 7323-7329 [PMID: 16437636]
34. Lee J, Rachmilewitz D, Raz E. Homeostatic effects of TLR9 signaling in experimental colitis. Ann N Y Acad Sci 2006; 1072: 351-355 [PMID: 17057215 DOI: 10.1196/annals.1326.022]
35. O'Hara JR, Feener TD, Fischer CD, Buret AG. Campylobacter jejuni disrupts protective Toll-like receptor 9 signaling in colonic epithelial cells and increases the severity of dextran sulfate sodium-induced colitis in mice. Infect Immun 2012; 80: 1563-1571 [PMID: 22311925 DOI: 10.1128/IAI.06066-11]
36. Sánchez-Muñoz F, Fonseca-Camarillo G, Villeda-Ramírez MA, Miranda-Pérez E, Mendivil EJ, Barreto-Zúñiga R, Uribe M, Bojalil R, Domínguez-López A, Yamamoto-Furusho JK. Transcript levels of Toll-Like Receptors 5, 8 and 9 correlate with inflammatory activity in Ulcerative Colitis. BMC Gastroenterol 2011; 11: 138 [PMID: 22185629 DOI: 10.1186/1471-230 X-11-138]
37. Sommariva M, De Cecco L, De Cesare M, Sfondrini L, Ménard S, Melani C, Delia D, Zaffaroni N, Pratesi G, Uva V, Tagliabue E, Balsari A. TLR9 agonists oppositely modulate DNA repair genes in tumor versus immune cells and enhance chemotherapy effects. Cancer Res 2011; 71: 6382-6390 [PMID: 21878529 DOI: 10.1158/0008-5472. CAN-11-1285]
38. Eiró N, González L, González LO, Andicoechea A, Fernández-Díaz M, Altadill A, Vizoso FJ. Study of the expression of toll-like receptors in different histological types of colorectal polyps and their relationship with colorectal cancer. J Clin Immunol 2012; 32: 848-854 [PMID: 22371291 DOI: 10.1007/ s10875-012-9666-3]
39. Rosa R, Melisi D, Damiano V, Bianco R, Garofalo S, Gelardi T, Agrawal S, Di Nicolantonio F, Scarpa A, Bardelli A, Tortora G. Toll-like receptor 9 agonist IMO cooperates with cetuximab in K-ras mutant colorectal and pancreatic cancers. Clin Cancer Res 2011; 17: 6531-6541 [PMID: 21890455 DOI: 10.1158/1078-0432. CCR-10-3376]
40. Yu D, Kandimalla ER, Bhagat L, Tang JY, Cong Y, Tang J, Agrawal S. 'Immunomers'--novel 3'-3'-linked CpG oligodeoxyribonucleotides as potent immunomodulatory agents. Nucleic Acids Res 2002; 30: 4460-4469 [PMID: 12384593 DOI: 10.1093/nar/gkf582]
41. Bardelli A, Siena S. Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer. J Clin Oncol 2010; 28: 1254-1261 [PMID: 20100961 DOI: 10.1200/ JCO.2009.24.6116]
42. Qiu J, Wang X, Guo X, Zhao C, Wu X, Zhang Y. Toll-like receptor 9 agonist inhibits ERalpha-mediated transactivation by activating NF-kappaB in breast cancer cell lines. Oncol Rep 2009; 22: 935-941 [PMID: 19724876 DOI: 10.3892/or_00000520]
43. Rath-Wolfson L, Purim O, Ram E, Morgenstern S, Koren R, Brenner B. Expression of estrogen receptor β1 in colorectal cancer: correlation with clinicopathological variables. Oncol Rep 2012; 27: 2017-2022 [PMID: 22407332]
44. Saleiro D, Murillo G, Benya RV, Bissonnette M, Hart J, Mehta RG. Estrogen receptor-β protects against colitis-associated neoplasia in mice. Int J Cancer 2012; 131: 2553-2561 [PMID: 22488198 DOI: 10.1002/ijc.27578]
45. Brody JD, Ai WZ, Czerwinski DK, Torchia JA, Levy M, Advani RH, Kim YH, Hoppe RT, Knox SJ, Shin LK, Wapnir I, Tibshirani RJ, Levy R. In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a phase I/II study. J Clin Oncol 2010; 28: 4324-4332 [PMID: 20697067 DOI: 10.1200/ JCO.2010.28.9793]
46. Thompson JA, Kuzel T, Drucker BJ, Urba WJ, Bukowski RM. Safety and efficacy of PF-3512676 for the treatment of stage IV renal cell carcinoma: an open-label, multicenter phase I/II study. Clin Genitourin Cancer 2009; 7: E58-E65 [PMID: 19815483 DOI: 10.3816/CGC.2009.n.025]
47. Hofmann MA, Kors C, Audring H, Walden P, Sterry W, Trefzer U. Phase 1 evaluation of intralesionally injected TLR9-agonist PF-3512676 in patients with basal cell carcinoma or metastatic melanoma. J Immunother 2008; 31: 520-527 [PMID: 18463532 DOI: 10.1097/CJI.0b013e318174a4df]
48. Yamada K, Nakao M, Fukuyama C, Nokihara H, Yamamoto N, Sekine I, Kunitoh H, Ohe Y, Ohki E, Hashimoto J, Tamura T. Phase I study of TLR9 agonist PF-3512676 in combination with carboplatin and paclitaxel in patients with advanced non-small-cell lung cancer. Cancer Sci 2010; 101: 188-195 [PMID: 19843072 DOI: 10.1111/j.1349-7006.2009.01361. x]
49. Katsuda M, Iwahashi M, Matsuda K, Miyazawa M, Nakamori M, Nakamura M, Naka T, Ojima T, Iida T, Yamaue H. [Peptide vaccine therapy with TLR-9 agonist for patients with esophageal squamous cell carcinoma]. Gan To Kagaku Ryoho 2011; 38: 1942-1944 [PMID: 22202246]
50. Tarhini AA, Leng S, Moschos SJ, Yin Y, Sander C, Lin Y, Gooding WE, Kirkwood JM. Safety and immunogenicity of vaccination with MART-1 (26-35, 27L), gp100 (209-217, 210M), and tyrosinase (368-376, 370D) in adjuvant with PF-3512676 and GM-CSF in metastatic melanoma. J Immunother 2012; 35: 359-366 [PMID: 22495394 DOI: 10.1097/ CJI.0b013e31825481fe]
51. Kim YH, Gratzinger D, Harrison C, Brody JD, Czerwinski DK, Ai WZ, Morales A, Abdulla F, Xing L, Navi D, Tibshirani RJ, Advani RH, Lingala B, Shah S, Hoppe RT, Levy R. In situ vaccination against mycosis fungoides by intratumoral injection of a TLR9 agonist combined with radiation: a phase 1/2 study. Blood 2012; 119: 355-363 [PMID: 22045986 DOI: 10.1182/blood-2011-05-355222]
52. Zent CS, Smith BJ, Ballas ZK, Wooldridge JE, Link BK, Call TG, Shanafelt TD, Bowen DA, Kay NE, Witzig TE, Weiner GJ. Phase I clinical trial of CpG oligonucleotide 7909 (PF-03512676) in patients with previously treated chronic lymphocytic leukemia. Leuk Lymphoma 2012; 53: 211-217 [PMID: 21812536 DOI: 10.3109/10428194.2011.608451]
53. Manegold C, van Zandwijk N, Szczesna A, Zatloukal P, Au JS, Blasinska-Morawiec M, Serwatowski P, Krzakowski M, Jassem J, Tan EH, Benner RJ, Ingrosso A, Meech SJ, Readett D, Thatcher N. A phase III randomized study of gemcitabine and cisplatin with or without PF-3512676 (TLR9 agonist) as first-line treatment of advanced non-small-cell lung cancer. Ann Oncol 2012; 23: 72-77 [PMID: 21464154 DOI: 10.1093/annonc/ mdr030]
54. Rayburn ER, Wang W, Zhang Z, Li M, Zhang R, Wang H. Experimental therapy of prostate cancer with an immunomodulatory oligonucleotide: effects on tumor growth, apoptosis, proliferation, and potentiation of chemotherapy. Prostate 2006; 66: 1653-1663 [PMID: 16927305 DOI: 10.1002/ pros.20485]
55. Henckaerts L, Pierik M, Joossens M, Ferrante M, Rutgeerts P, Vermeire S. Mutations in pattern recognition receptor genes modulate seroreactivity to microbial antigens in patients with inflammatory bowel disease. Gut 2007; 56: 1536-1542 [PMID: 17595233 DOI: 10.1136/gut.2007.125468]
56. Rachmilewitz D, Karmeli F, Takabayashi K, Hayashi T, Leider-Trejo L, Lee J, Leoni LM, Raz E. Immunostimulatory DNA ameliorates experimental and spontaneous murine colitis. Gastroenterology 2002; 122: 1428-1441 [PMID: 11984528 DOI: 10.1053/gast.2002.32994]
57. Musch E, Lutfi T, von Stein P, Zargari A, Admyre C, Malek M, Löfberg R, von Stein OD. Topical treatment with the toll-like receptor agonist DIMS0150 has potential for lasting relief of symptoms in patients with chronic active ulcerative colitis by restoring glucocorticoid sensitivity. Inflamm Bowel Dis 2013; 19: 283-292 [DOI: 10.1002/ibd.23019]
58. Liu L, Shen L, Liu X, Yu Y, Li Y, Wang L, He C, Sun J, Li B. A safety study of a B-class CpG ODN in Sprague-Dawley rats. J Appl Toxicol 2012; 32: 60-71 [PMID: 21538408 DOI: 10.1002/ jat.1683]
59. Chi H, Barry SP, Roth RJ, Wu JJ, Jones EA, Bennett AM, Flavell RA. Dynamic regulation of pro-and anti-inflammatory cytokines by MAPK phosphatase 1 (MKP-1) in innate immune responses. Proc Natl Acad Sci USA 2006; 103: 2274-2279 [PMID: 16461893 DOI: 10.1073/pnas.0510965103]
60. Matesic D, Lenert A, Lenert P. Modulating toll-like receptor 7 and 9 responses as therapy for allergy and autoimmunity. Curr Allergy Asthma Rep 2012; 12: 8-17 [PMID: 22086297 DOI: 10.1007/s11882-011-0233-4]
61. Hochrein H, Wagner H. Of men, mice and pigs: looking at their plasmacytoid dendritic cells [corrected]. Immunology 2004; 112: 26-27 [PMID: 15096180 DOI: 10.1111/ j.1365-2567.2004.01878. x]
62. Krieg AM. CpG motifs: the active ingredient in bacterial extracts? Nat Med 2003; 9: 831-835 [PMID: 12835699 DOI: 10.1038/nm0703-831]
63. Guzylack-Piriou L, Balmelli C, McCullough KC, Summerfield A. Type-A CpG oligonucleotides activate exclusively porcine natural interferon-producing cells to secrete interferon-alpha, tumour necrosis factor-alpha and interleukin-12. Immunology 2004; 112: 28-37 [PMID: 15096181 DOI: 10.1111/ j.1365-2567.2004.01856. x]